Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Histidine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS1 known ✓ | P23219 | 1/20 | 0.42 |
| ▸ | SLC7A5 | Q01650 | 3/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 3/20 | 0.42 |
| ▸ | ALPI | P09923 | 1/20 | 0.42 |
| ▸ | XIAP | P98170 | 1/20 | 0.42 |
| ▸ | GRIA2 | P42262 | 4/20 | 0.40 |
| ▸ | GRIA1 | P42261 | 3/20 | 0.40 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.40 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 2/20 | 0.39 |
| ▸ | BLM | P54132 | 2/20 | 0.39 |
| ▸ | PMP22 | Q01453 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Histidine SCHEMBL27153440 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL94550 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL30286660 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL16893958 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| D-Histidine SCHEMBL8002457 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL139654 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL670490 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL3985696 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL16893957 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI | |
| Histidine SCHEMBL3985692 | 1.00 | SLC7A5 (0.46) | SLC7A5CYP3A4CYP1A2PKMALPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 11612 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-121490076-B | Stable anti-human MASP2 monoclonal antibody preparation | Shanghai Maiji Pharmaceutical Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| CN-122095249-A | Development of high throughput assays for identifying al3+ traces in biopharmaceutical products | — | 2026-05-26 | — | — | CN | claimed |
| CN-122081234-A | Low-serum MSB1 suspension medium and chicken infectious anemia virus inactivated vaccine | — | 2026-05-26 | — | — | CN | claimed |
| CN-121379932-B | Culture medium for high-density serum-free suspension culture of BHK-21 cells and application thereof | Zhongsheng tianxinhe (Wuxi) Biotechnology Co.,Ltd. (CN) | 2026-05-26 | — | — | CN | claimed |
| WO-2026102693-A1 | PCSK9 ANTIBODY AND USE THEREOF | 北京天广实生物技术股份有限公司 | 2026-05-21 | — | — | WO | claimed |
| US-20260139045-A1 | STABILIZED FORMULATIONS CONTAINING ANTI-ANGPTL3 ANTIBODIES | REGENERON PHARMACEUTICALS INC (US) | 2026-05-21 | — | — | US | claimed |
| WO-2026106498-A1 | PERFUSION FLUID, METHODS OF PRODUCING PERFUSION FLUID, AND ITS USES | NanoSanguis S.A. (PL) | 2026-05-21 | — | — | WO | claimed |
| US-20260139047-A1 | PHARMACEUTICAL COMPOSITION CONTAINING FUSION PROTEIN | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2026-05-21 | — | — | US | claimed |
| EP-4744487-A1 | FLUID, METHODS OF PRODUCING FLUID, AND ITS USES | NanoSanguis S.A. (PL) | 2026-05-20 | — | — | EP | claimed |
| EP-4566674-B1 | ANTIBODY COMPOSITIONS AND METHODS OF USE THEREOF | BRISTOL MYERS SQUIBB CO (US) | 2026-05-20 | — | — | EP | claimed |
| EP-0336987-A1 | Feed additive for ruminants | MITSUBISHI KASEI CORPORATION (JP) | 1989-10-18 | — | — | EP | claimed |
| US-4864031-A | Process for the resolution of D,L-racemic mixtures | YEDA RESEARCH AND DEVELOPMENT CO., LTD. (IL) | 1989-09-05 | — | — | US | claimed |
| US-4600708-A | MASKING TASTE OR ANESTHESIA CHARACTERISTICS USING AMINO ACID OR LECITHIN | AMERICAN HOME PRODUCTS CORPORATION (US) | 1986-07-15 | — | — | US | claimed |
| EP-0054635-B1 | PROTECTIVE SOLUTION FOR HEART AND KIDNEY, AND MANUFACTURING PROCESS | Dr. Franz Köhler Chemie GmbH (DE) | 1985-02-13 | — | — | EP | claimed |
| US-4415556-A | ANTIISCHEMIC AGENTS CONTAINING ALPHA-KETOGLUTARIC ACID; SURGERY; TRANSPLANTS | DR. FRANZ KOHLER CHEMIE GMBH (DE) | 1983-11-15 | — | — | US | claimed |
| US-4390722-A | CRYSTALLIZATION FROM SUPERSATURATED SOLUTION USING AMINO ACID AS AS CRYSTAL INHIBITOR | YEDA RESEARCH AND DEVELOPMENT COMPANY LTD. (IL) | 1983-06-28 | — | — | US | claimed |
| EP-0012272-B1 | PROTECTING SOLUTION FOR HEART AND KIDNEYS AND PROCESS FOR ITS MANUFACTURE | Dr. Franz Köhler Chemie KG (DE) | 1981-12-30 | — | — | EP | claimed |
| EP-0008171-B1 | HAIR TREATMENT COMPOSITION AND METHOD | UNILEVER PLC (GB) | 1981-11-11 | — | — | EP | claimed |
| EP-0012272-A1 | Protecting solution for heart and kidneys and process for its manufacture | Dr. Franz Köhler Chemie KG (DE) | 1980-06-25 | — | — | EP | claimed |
| US-4035513-A | COSMETICS | SHISEIDO CO., LTD. (JA) | 1977-07-12 | — | — | US | claimed |